ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J01CR02 | G | Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg | 6457 | 96224/11 | MEGAMOX-JPI | 625mg | 20 | Tablet | Oral | Droguerie de l'Union | Jazeera Pharmaceutical Industries | Saudi Arabia | 245,923 L.L | 23.08 | A1 | Jazeera Pharmaceutical Industries | Saudi Arabia | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J01CR02 | B | Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg | 9849 | 179118/1 | AUGMENTIN | 625mg | 20 | Tablet | Oral | Abela Frères S.A.L. | Pharmaline SAL Licensed by Glaxo SmithKline Export Ltd , UK | Lebanon | 466,459 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01CR02 | G | Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg | 1132 | 38875/96 | AMOCLAN FORTE | 625mg | 15 | Tablet | Oral | Droguerie de l'Union | Al-Hikma Pharmaceuticals | Jordan | 170,668 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01CR02 | G | Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg | 8322 | 84015/1 | CURAM | 625mg | 20 | Tablet, film coated | Oral | Khalil Fattal & Fils S.A.L. | Pharmaline under license from Sandoz GmbH, Austria | Lebanon | 375,529 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01CR02 | G | Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg | 1478 | 974455/00 | JULMENTIN FORTE | 625mg | 20 | Tablet, film coated | Oral | Pharmanet Drugstore S.A.R.L. | Julphar | United Arab Emirates | 245,923 L.L | 23.08 | A1 | 2/5/2024 | 0 |